Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆
Aug 2026· ESMO Open· Vol 11· 0 citations· 23 references
Medicine
TL;DR
First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.
Abstract
Background In the randomized, double-blind, phase III RATIONALE-306 trial, patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous-cell carcinoma (ESCC) treated with tislelizumab plus chemotherapy in the intent-to-treat population and in the programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥5% subgroup experienced clinically meaningful overall survival (OS) benefit compared with placebo plus chemotherapy at the interim analysis and minimum 3-year follow-up. We report post hoc, exploratory, longer-term outcomes at study closeout with minimum 45.2-month follow-up in patients with PD-L1 TAP score ≥5% per European Medicines Agency recommendation. Patients and methods Patients were randomly assigned (1 : 1) to receive tislelizumab 200 mg or placebo every 3 weeks plus investigator-chosen chemotherapy. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), safety, and quality of life (QoL). Results Of 649 randomly allocated patients, 55.2% had PD-L1 TAP score ≥5% (tislelizumab plus chemotherapy, n = 172; placebo plus chemotherapy, n = 186). At 45.2-month minimum follow-up, tislelizumab plus chemotherapy improved OS [median 19.1 versus 10.0 months; hazard ratio (HR) 0.61] and PFS (median 8.2 versus 5.5 months; HR 0.50) compared with placebo plus chemotherapy. ORR was 71.5% versus 41.4%; median DoR was 7.1 versus 5.4 months, respectively. QoL was similar overall between arms, with tislelizumab plus chemotherapy trending toward better global health and pain reduction. Any-grade treatment-related adverse events (TRAEs) occurred in 97.7% (tislelizumab plus chemotherapy) versus 98.4% (placebo plus chemotherapy) and grade ≥3 TRAEs in 70.2% versus 66.5%, respectively. The most common grade ≥3 TRAEs were decreased neutrophil count (35.1% versus 31.9%), anemia (13.5% versus 11.4%), and decreased white blood cell count (12.3% versus 17.8%). Treatment-emergent adverse events with ≥5% difference in incidence between arms at interim analysis decreased substantially after 12 months. Conclusion First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.
Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...
S. Rha, L. Wyrwicz, P. Yanez et al.· ESMO Open· 1 citation· ⚡1
RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...
H. Yoon, Ken Kato, E. Raymond et al.· Nature Communications· 0 citations
BACKGROUND
Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...
H. Wakelee, J. Spicer, S. Gao et al.· Annals of Oncology· 1 citation
Importance
In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at interim analysis 1 (media...
Kosei Hasegawa, N. Colombo, Krishnansu S. Tewari et al.· JAMA Oncology· 0 citations
It is suggested that crizotinib should not be recommended as an adjuvant therapy for patients with resected, early-stage ALK-positive NSCLC and that crizotinib should not be recommended as an adjuvant therapy for patients with resected ALK-positive NSCLC.
D. E. Gerber, Yating Wang, C. Langer et al.· The Lancet Respiratory Medic...· 2 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
Neoadjuvant chemotherapy combined with PD-1 inhibitors has application potential for locally advanced esophageal squamous cell carcinoma (ESCC), but there is no prospective evidence for the optimal timing of the dose (sequential vs. concurrent)....
Yan Zheng, Jiwei Wu, Ling-Di Zhao et al.· Diseases of the esophagus· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.